Jung Choi Acquires 65,000 Shares of ANNX
Insider Jung Choi purchased 65,000 shares of ANNX on June 11, 2026.
Key Points
- Jung Choi acquired 65,000 shares of ANNX on June 11, 2026, with no cost per share recorded.
- ANNX shares are trading around $4.81, with significant institutional activity from Redmile Group and BlackRock.
- Analysts from Goldman Sachs and Chardan Capital have set price targets of $7 and $16 respectively.
Jung Choi, an insider at ANNX, purchased 65,000 shares of the company on June 11, 2026. The transaction did not record a cost per share, and it's not part of a pre-planned program.
Other Institutional Activity in ANNX
Redmile Group, LLC increased its holdings in ANNX by 4,499,124 shares, ending with 14,549,768 shares valued at approximately $80.6 million. BlackRock, Inc. also grew its position, adding 1,978,075 shares to hold a total of 10,938,509 shares worth about $60.6 million. FMR LLC added 413,178 shares, bringing its total to 10,635,648 shares valued at $58.9 million. On the other hand, BVF Inc/IL reduced its stake by 429,907 shares, now holding 8,698,173 shares valued at $48.2 million. State Street Corp increased its holdings significantly by 2,267,070 shares, totaling 6,919,255 shares valued at $38.3 million.
ANNX Stock Snapshot
Shares of ANNX are trading at approximately $4.81. The stock has seen recent interest from institutional investors, which may influence its market performance. However, specific financial metrics like market capitalization and P/E ratio are not available.
Insider Buying and Selling at ANNX
On June 11, 2026, several insiders at ANNX made significant stock purchases. Jung Choi, along with William Jones Jr., Bettina Cockroft, William Waddill, and William Carson, each acquired 65,000 shares with no recorded purchase price. Additionally, Ted Yednock, EVP & Chief Innovation Officer, bought 30,646 shares at an average price of $1.85.
Analysts Set New Price Targets
On May 12, 2026, Goldman Sachs initiated coverage of ANNX with a 'hold' rating and a price target of $7. Earlier in the year, on March 20, 2026, Chardan Capital maintained its 'buy' rating with a target of $16. The consensus among analysts reflects a positive outlook, with several maintaining 'buy' ratings.
About ANNX
ANNX operates within the biotechnology sector, focusing on developing innovative therapies for unmet medical needs. The company is headquartered in the United States and is involved in various stages of drug development and commercialization.
Bottom Line
The insider purchase by Jung Choi is a notable event, reflecting confidence in ANNX's prospects. Institutional investors have also shown significant interest, with major players adjusting their positions. Analyst coverage suggests varied price targets, indicating differing expectations for the company's future performance. Keep in mind that insider and institutional activities are backward-looking and may not represent current positions.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.